首页|布地奈德福莫特罗粉吸入剂联合盐酸左西替利嗪治疗过敏性鼻炎-哮喘综合征的效果及对过敏反应、炎性因子水平的影响

布地奈德福莫特罗粉吸入剂联合盐酸左西替利嗪治疗过敏性鼻炎-哮喘综合征的效果及对过敏反应、炎性因子水平的影响

扫码查看
目的 探讨布地奈德福莫特罗粉吸入剂联合盐酸左西替利嗪治疗过敏性鼻炎-哮喘综合征(CARAS)的效果及对过敏反应、炎性因子水平的影响。方法 选取2019 年 2 月至 2022 年 3 月收治的 100 例CARAS患者为研究对象,采用随机数字表法将其分为对照组与观察组,各50例。对照组给予盐酸左西替利嗪治疗,观察组在对照组基础上加用布地奈德福莫特罗粉吸入剂治疗。比较两组的治疗效果。结果 观察组的治疗总有效率高于对照组,差异具有统计学意义(P<0。05)。治疗前,两组的鼻痒、喷嚏、鼻塞、呼吸困难评分比较,差异无统计学意义(P>0。05);治疗后,观察组的鼻痒、喷嚏、鼻塞、呼吸困难评分低于对照组,差异具有统计学意义(P<0。05)。治疗前,两组的白细胞介素-22(IL-22)、白细胞介素-8(IL-8)及免疫球蛋白E(IgE)水平比较,差异无统计学意义(P>0。05);治疗后,观察组的IL-22、IL-8、IgE水平低于对照组,差异具有统计学意义(P<0。05)。治疗前,两组的用力肺活量(FVC)、第 1 秒用力呼气容积(FEV1)比较,差异无统计学意义(P>0。05);治疗后,观察组的FVC、FEV1 高于对照组,差异具有统计学意义(P<0。05)。结论 布地奈德福莫特罗粉吸入剂联合盐酸左西替利嗪治疗CARAS的效果明显,能抑制炎性因子水平,减轻过敏反应,从而改善患者肺功能。
Effect of budesonide formoterol powder inhalation combined with levocetirizine hydrochloride in the treatment of combined allergic rhinitis and asthma syndrome and its influences on allergic reaction and inflammatory factors levels
Objective To investigate the effect of budesonide formoterol powder inhalation combined with levocetirizine hydrochloride in the treatment of combined allergic rhinitis and asthma syndrome(CARAS)and its influences on allergic reaction and inflammatory factors levels.Methods A total of 100 patients with CARAS admitted from February 2019 to March 2022 were selected as the research objects,and the patients were divided into control group and observation group by random number table method,with 50 cases in each group.The control group was treated with levocetirizine hydrochloride,and the observation group was treated with budesonide formoterol powder inhalation on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the scores of nasal itching,sneezing,nasal congestion and dyspnea between the two groups(P>0.05);after treatment,the scores of nasal itching,sneezing,nasal congestion and dyspnea in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of interleukin-22(IL-22),interleukin-8(IL-8)and immunoglobulin E(IgE)between the two groups(P>0.05);after treatment,the levels of IL-22,IL-8 and IgE in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in forced vital capacity(FVC)and forced expiratory volume in the first second(FEV1)between the two groups(P>0.05);after treatment,the FVC and FEV1 in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion The budesonide formoterol powder inhalation combined with levocetirizine hydrochloride in the treatment of CARAS has a significant effect.It can inhibit the levels of inflammatory factors,relieve allergic reactions,and improve the lung function of patients.

budesonide formoterol powder inhalationlevocetirizine hydrochloridecombined allergic rhinitis and asthma syndromeallergic reactioninflammatory factor

黄艳飞、刘晓东、牛永亮

展开 >

神木市医院,陕西 榆林,719300

布地奈德福莫特罗粉吸入剂 盐酸左西替利嗪 过敏性鼻炎-哮喘综合征 过敏反应 炎性因子

陕西省卫生健康委2022年度卫生健康科研项目

2022C006

2024

临床医学研究与实践

临床医学研究与实践

ISSN:
年,卷(期):2024.9(21)